{ "answer": "Novo Nordisk underwent a giant restructuring in Autumn 2025, impacting 9,000 roles globally, 5,000 of which were in Denmark. Digital was heavily impacted and my role was one of those.\n\nYou could ask what I'm looking for, or what I've been doing since leaving.", "section": "TQ.LEAVING", "source": "Tom's own account", "tier": "self-reported", "strength": null, "year": "2025", "direct_answers": [ "Garden leave from the end of October 2025; employment ended at the end of February 2026." ], "references": null, "follow_ups": [ "what are you looking for", "what are you doing now", "tell me about your career journey" ], "score": 0.95, "matches": [ { "section": "TQ.LEAVING", "answer": "Novo Nordisk underwent a giant restructuring in Autumn 2025, impacting 9,000 roles globally, 5,000 of which were in Denmark. Digital was heavily impacted and my role was one of those.\n\nYou could ask what I'm looking for, or what I've been doing since leaving.", "source": "Tom's own account", "tier": "self-reported", "year": "2025", "strength": null, "score": 0.95, "direct_answers": [ "Garden leave from the end of October 2025; employment ended at the end of February 2026." ], "references": null }, { "section": "NOVO", "answer": "Novo Nordisk is a global pharmaceutical company, best known for its treatments in obesity and diabetes. I worked at Novo for almost 6 years (2020 to 2026).\n\nI joined Novo as a Senior Product Manager, to build a digital patient solution for Wegovy, a then-unheard-of weight loss medicine. I led the full product lifecycle end to end, and it was really a stealth transformation project, where I could bring my learnings from LEO but to in-house transformation.\n\nI was later asked to scale learnings from Wegovycare across the product organisation and was promoted to Associate Product Director. In this role, I had a much wider remit, and worked on high-impact, cross-functional projects across the organisation.\n\nWant to know more? Ask about either of my roles, the transformation work, or specific projects like Wegovy or the GenAI proof of concept.", "source": "Tom's own account", "tier": "self-reported", "year": null, "strength": null, "score": 0.74, "direct_answers": [ "Company context: Novo Nordisk is about 70,000 people globally. I worked in the digital health unit, about 100 people; the Wegovycare product team was around 10." ], "references": { "period": "Novo Nordisk, 2020-2026", "count": 5, "url": "https://takenbyninjas.com/for-agents/recommendations/#novo", "tier": "attested", "note": "References for the role, not for this claim." } }, { "section": "NOVO.R1.TRANSFORM", "answer": "Innovation Labs are an interesting idea, but unfortunately rarely work in practice. I still believed there was enormous potential in healthcare, so this time wanted to try it from the inside - transformation by doing.\n\nI got my first opportunity in my final round job interview at Novo, when I convinced the business to set-aside their solution-first brief, and to talk to patients and start with the problem instead. I was fortunate enough to be offered the role, and use this as a mandate to completely reinvent their ways of working. We were the first product team to interview patients, run discovery, make prototypes, co-create with markets and so on. It wasn't straight-forward and took persuasion and a leap of faith from our stakeholders, but the results spoke for themselves.\n\nI was asked to scale these learnings across the product organisation and was promoted to Associate Product Director.", "source": "Tom's own account", "tier": "self-reported", "year": null, "strength": "Led", "score": 0.62, "direct_answers": [ "Wegovycare launched on time and on budget, with 10% penetration in the first national market.", "Borrowed an anthropologist from another division & proved the value. It later became the Insights team." ], "references": { "period": "Novo Nordisk, 2020-2026", "count": 5, "url": "https://takenbyninjas.com/for-agents/recommendations/#novo", "tier": "attested", "note": "References for the role, not for this claim." } }, { "section": "NOVO.R1", "answer": "Senior Product Manager at Novo Nordisk (Mar 2020 - Feb 2022), building Wegovycare - a retention-focused digital service to increase repeat prescriptions for Wegovy.\n\nI led the full product lifecycle end to end, but it was really a stealth transformation project, where I could bring my learnings from LEO but this time to in-house transformation.\n\nKey achievements:\n- Led the full product life-cycle, introducing discovery, rapid prototyping, iterative development, and automated documentation to the organisation.\n- Automated documentation and shifted release cycles from yearly to bi-monthly in high-regulation environment, enabling iterative learning.\n- Built a weight-loss prediction algorithm from concept to prototype (later spun out into a new API product)\n- Achieved 10% penetration in our first national market\n\nI was asked to scale these learnings across the product organisation and was promoted to Associate Product Director.", "source": "Tom's own account", "tier": "self-reported", "year": "2020-2022", "strength": "Led", "score": 0.61, "direct_answers": [ "Scaling Wegovycare: release cycles were yearly, with heavy documentation in a high-regulation environment, and every market needed its own version. Designed for scale (modular architecture, feature flags, CMS and translation pipeline), automated the documentation, and release cycles went from yearly to bi-monthly; adopted by multiple markets.", "Patient interviews surfaced two insights: every patient's journey is different, but everyone wants to know the same things - how much weight will I lose, is this normal, am I on track. Those three questions became the core loop, and the weight-loss prediction model answered the first.", "The brief I was given in my final-round interview was solution-first: a set of standalone features the business thought would help. Nobody had spoken to patients.", "Through research identified every user-journey is different. Built risk-profiling engine combining clinical data, usage signals, & PROMs to identify drop-off risks.", "Applied consumer marketing playbook to act on risks, personalising experience for each patient. Built profiling and customisation engine to create an interactive magazine.", "Digital patient platform for obesity medicine, built to scale. Designed for scaling: modular architecture, feature flags, integrated CMS & translation pipeline, and systematised cocreation with markets.", "First digital Novo product to successfully scale. Made Novo's first digital health product adopted by multiple markets.", "Led cross-functional team of 10. Set vision, implemented OKRs & used qual-quant signals to steer priorities and shape the roadmap.", "Identified a key growth lever. Created a weight-loss prediction model in Excel, now spun-out to a Bayesian API service.", "Title: Senior Product Manager; the internal title was Product Owner. Same role.", "Adoption, Wegovycare: involved affiliates early to generate learnings & create buy-in; systematised cocreation with markets; 10% penetration in our first national market; biggest adoption of any digital patient solution at Novo; the resistance was a \"you're not working if you're not coding\" culture, and it took persuasion and a leap of faith from our stakeholders. At LEO, made rapid prototyping and direct user interviews standard practice across all product teams.", "Wegovycare was built as non-SaMD and bound by the drug label: it could only recommend the standard titration. The weight-loss prediction model started as an Excel spreadsheet, was spun out as a Bayesian API service, and the team later extended it to HbA1c." ], "references": { "period": "Novo Nordisk, 2020-2026", "count": 5, "url": "https://takenbyninjas.com/for-agents/recommendations/#novo", "tier": "attested", "note": "References for the role, not for this claim." } } ], "facts": null, "withheld": 0, "human_version": "https://takenbyninjas.com/projects/tombot/" }